Abbott Gets a Brass Ring
Executive Summary
Chiron Corp. has licensed rights to HCV nucleic acid diagnostics to Abbott Laboratories on a semi-exclusive basis for use in clinical applications, excluding blood banking. HCV is one of the most coveted diagnostics tests and Chiron, which holds the patent on has been very cautious about licensing rights; so far, it has licensed immunoassay rights to two companies, two for blood banking only, and nucleic acid rights to Bayer AG. lYou may also be interested in...
Safe Blood At Any Cost?
With AIDS and HCV under control, companies large and small are looking to protect the blood supply from a range of known and as yet unknown pathogens, which pose potential threats. Near-term attention is focusing on emerging pathogen inactivation technologies, which are moving closer to the clinic, even as questions linger about their cost effectiveness and toxicity.
QUOTED. 28 January 2020. Steven Falowski.
Abbott is encouraged by results from two studies of its Proclaim XR neurostimulation system for chronic pain, presented at the annual North American Neuromodulation Society (NANS) meeting in Las Vegas. See what Steven Falowski of Neurosurgical Associates of Lancester in Pennsylvania said about it here.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports